CHD3: A Potential Drug Target for Cancer and Other Diseases (G1107)

Target Name: CHD3

NCBI ID: G1107

CHD3

CHD3: A Potential Drug Target for Cancer and Other Diseases

CHD3 (CHromosome 22, long arm alpha-2) is a gene that has been identified as a potential drug target for the treatment of various diseases, including cancer. The gene is located on chromosome 22, which is the last chromome on the X chromosome and is known as the \"reversion-incompatible\" region. This gene is associated with a range of physiological processes, including cell division, apoptosis (programmed cell death), and chromosomal stability.

One of the key features of CHD3 is its role in regulating cell division. The gene is known to be involved in the control of mitosis, which is the process by which a cell divides and creates a new copy of itself. Mutations in the CHD3 gene have been linked to changes in cell division that can lead to the development of cancer.

In addition to its role in cell division, CHD3 is also involved in regulating apoptosis. Apoptosis is a natural process that helps the body eliminate damaged or dysfunctional cells. However, when apoptosis is not properly regulated, it can lead to the development of cancer. The CHD3 gene has been shown to play a role in regulating apoptosis, which may make it an attractive target for drug developers.

Another important function of CHD3 is its role in maintaining chromosomal stability. Chromosomal instability is a hallmark of cancer, and is associated with the development of many diseases, including cancer. The CHD3 gene has been shown to play a role in maintaining chromosomal stability, which may help to reduce the risk of chromosomal instability and the development of cancer.

In conclusion, CHD3 is a gene that has the potential to be a drug target for the treatment of various diseases. Its role in regulating cell division, apoptosis, and chromosomal stability makes it an attractive target for drug developers. Further research is needed to fully understand the potential of CHD3 as a drug target and to develop safe and effective treatments.

Protein Name: Chromodomain Helicase DNA Binding Protein 3

Functions: ATP-dependent helicase that binds and distorts nucleosomal DNA (PubMed:28977666). Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:9804427, PubMed:30397230, PubMed:16428440, PubMed:28977666). Involved in transcriptional repression as part of the NuRD complex (PubMed:27068747). Required for anchoring centrosomal pericentrin in both interphase and mitosis, for spindle organization and centrosome integrity (PubMed:17626165)

The "CHD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets